Atopic dermatitis (AD) is typically a big issue during early childhood. But it also afflicts up to 5% of adults. Mild cases, which are virtually always managed in primary care, are usually ...

ORLANDO -- Among children taking the monoclonal antibody dupilumab (Dupixent) for atopic dermatitis, more than a quarter of ocular complications developed after a year, according to a retrospective ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, considers dupilumab the "gold standard" for itch control in patients with atopic dermatitis due to its minimal adverse effects.

Please provide your email address to receive an email when new articles are posted on . Researchers compared dupilumab use with other and with no systemic therapy. Dupilumab inhibits IL-4 and IL-13, ...

Please provide your email address to receive an email when new articles are posted on . EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics ...

Dupixent is a prescription medication that can help manage chronic inflammatory conditions in children, such as eczema, asthma, and eosinophilic esophagitis. It can be exhausting for a child to ...

The FDA has approved dupilumab (Dupixent) to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older with a history of sinonasal surgery. The approval makes the drug the ...